Update on the pharmacotherapy of obesity

Annals of Pharmacotherapy

Volumn 32, Issue 1, 1998, Pages 88-102

  Cerulli, Jennifer ^a   Lomaestro, Ben M ^b   Malone, Margaret ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ALBANY MEDICAL CENTER   (United States)

Author keywords

Appetite suppressants; Digestive inhibitors; Hormonal manipulation; Obesity; Thermogenic agents

Indexed keywords

4 [2 [(2 HYDROXY 2 PHENYLETHYL)AMINO]PROPYL]BENZOIC ACID METHYL ESTER HYDROGEN MALEATE; 4 [2 [(2 HYDROXY 3 PHENOXYPROPYL)AMINO]ETHOXY] N (2 METHOXYETHYL)PHENOXYACETAMIDE; 4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID METHYL ESTER; 4 [3 [BIS(BETA HYDROXYPHENETHYL)AMINO]BUTYL]BENZAMIDE; 5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; ANOREXIGENIC AGENT; ANTIHYPERTENSIVE AGENT; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CAFFEINE; DEXFENFLURAMINE; EPHEDRINE; FENFLURAMINE; GALANIN; LEPTIN; MONOAMINE OXIDASE INHIBITOR; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; PHENTERMINE; PHENYTOIN; PRAVASTATIN; SEROTONIN AGONIST; SIBUTRAMINE; SUCROSE POLYESTER; TETRAHYDROLIPSTATIN; WARFARIN;

ADULT; ANOREXIA; ARTICLE; ASTHENIA; BREAST CARCINOMA; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OBESITY; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SATIETY; SINGLE BLIND PROCEDURE; SOMNOLENCE; TACHYCARDIA; TREMOR; VALVULAR HEART DISEASE; WEIGHT REDUCTION; XEROSTOMIA;

ADRENERGIC AGENTS; APPETITE DEPRESSANTS; BODY TEMPERATURE REGULATION; DIGESTION; DRUG INTERACTIONS; FAT SUBSTITUTES; HUMANS; LEPTIN; LIPASE; OBESITY; PROTEINS; RANDOMIZED CONTROLLED TRIALS; SEROTONIN AGENTS;

EID: 0031885225     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.17039     Document Type: Article

References (93)

1. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults: the national health and nutrition examination surveys, 1960 to 1991. JAMA 1994;272:205-11.
2. Wolf AM, Colditz GA. Social and economic effects of body weight in the United States. Am J Clin Nutr 1996;63(suppl):466S-9S.
3. Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med 1993;119(7 pt 2):655-60.
4. Bray GA. Pathophysiology of obesity. Am J Clin Nutr 1992;55(suppl): 488S-94S.
5. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-32.
6. Bray GA. The new era of drug treatment. Pharmacologic treatment of obesity: symposium overview. Obes Res 1995;3(suppl 4):415s-7s.
7. Leibowitz SF. Brain peptides and obesity: pharmacologic treatment. Obes Res 1995;3(suppl 4):573s-89s.
8. Baez M, Kursur JD, Helton LA, Wainscott DB, Nelson DLG. Molecular biology of serotonin receptors. Obes Res 1995;3(suppl 4):441s-7s.
9. 3-adrenoceptor agonists in the treatment of obesity and diabetes. Int J Obes 1996;20:191-9.
10. Caro JF, Sinha MK, Kolaczynski JW, Zhang PL, Considine RV. Leptin: the tale of an obesity gene. Diabetes 1996;45:1455-62.
11. Caterson ID. Management strategies for weight control. Drugs 1990;39 (suppl 3):20-32.
12. National Institutes of Health. Gastrointestinal surgery for severe obesity: Consensus Development Conference statement. Ann Intern Med 1991; 115:956-61.
13. Meisler JG, St. Jeor S. American Health Foundation Roundtable on Healthy Weight: foreword. Am J Clin Nutr 1996;63(suppl):409s-11s.
14. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes 1992;16:1-19.
15. Stunkard AJ. Current views on obesity. Am J Med 1996;100:230-6.
16. National Task Force on the Prevention of Obesity. Long-term pharmacotherapy in the management of obesity. JAMA 1996;276:1907-15.
17. Physicians' desk reference. 51st ed. Montvale, NJ: Medical Economics Company, 1997.
18. Cardinale V, ed. 1997 Drug topics red book. Montvale, NJ: Medical Economics Company, 1997.
19. Goldstein DJ, Rampey AH, Roback PJ, Wilson MG, Hamilton SH, Sayler ME, et al. Efficacy and safety of long term fluoxetine treatment of obesity - maximizing success. Obes Res 1995;3(suppl 4):481s-90s.
20. Bray GA. Evaluation of drugs for treating obesity. Obes Res 1995;3(suppl 4): 425s-34s.
21. Bray GA. Use and abuse of appetite-suppressant drugs in the treatment of obesity. Ann Intern Med 1993;119(7 pt 2):707-13.
22. Goldstein DJ, Potvin JH. Long term weight loss: the effect of pharmacologic agents. Am J Clin Nutr 1994;60:647-57.
23. Wurtman RJ, Wurtman JJ. Brain serotonin, eating behavior, and fat intake. Obes Res 1995;3(suppl 4):477s-80s.
24. Blundell JE, Lawton CL, Halford JCG. Serotonin, eating behavior and fat intake. Obes Res 1995;3(suppl 4):471s-6s.
25. Scalfi L, D'Arrigo E, Carradente V, Coltori A, Contaldo F. The acute effect of dexfenfluramine on resting metabolic rate and post prandial thermogenesis in obese subjects: a double blind placebo controlled study. Int J Obes Relat Metab Disord 1993;17:91-6.
26. Goodall EM, Cowen PJ, Franklin M, Silverstone T. Ritanserin attenuates anorectic, endocrine and thermic responses to o-fenfluramine in human volunteers. Psychopharmacology 1993;112:461-6.
27. Weintraub M, Sundaresan PR, Madan M, Schuster B, Balder A, Lasagna L, et al. Long term weight control study I (weeks 0 to 34): the enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther 1992;51: 586-94.
28. Weintraub M, Sundaresan PR, Schuster B, Ginsberg G, Madan M, Balder A, et al. Long term weight control study II (weeks 34 to 104): an open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medications as adjuncts to behavior modification, caloric restriction, and exercise. Clin Pharmacol Ther 1992;51:595-601.
29. Weintraub M, Sundaresan PR, Schuster B, Moscucci M, Stein EC. Long term weight control study in (weeks 104 to 156): an open label study of dose adjustment of fenfluramine and phentermine. Clin Pharmacol Ther 1992;51:602-7.
30. Weintraub M, Sundaresan PR, Schuster B, Averbuch M, Stein EC, Cox C, et al. Long term weight control study IV: (weeks 156-190): the second double blind phase. Clin Pharmacol Ther 1992;51:608-14.
31. Weintraub M, Sundaresan PR, Schuster B, Averbuch M, Stein EC, Byrne L. Long term weight control study V (weeks 190-210): follow up of participants after cessation of medication. Clin Pharmacol Ther 1992; 51:615-8.
32. Weintraub M, Sundaresan PR, Cox C. Long term weight control study VI: individual participant response patterns. Clin Pharmacol Ther 1992; 51:619-33.
33. Weintraub M. Long term weight control study: conclusions. Clin Pharmacol Ther 1992;51:642-6.
34. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:581-8.
35. Sporer KA. The serotonin syndrome: implicated drugs, pathophysiology and management. Drug Saf 1995;13(2):94-104.
36. McTavish D, Heel RC. Dexfenfluramine. Drugs 1992;43:713-33.
37. Davis R, Faulds D. Dexfenfluramine: an updated review of its therapeutic use in the management of obesity. Drugs 1996;52:696-724.
38. Guy-Grand B. Clinical studies with dexfenfluramine from past to future. Obes Res 1995;3(suppl 4):491s-6s.
39. Guy-Grand B, Apfelbaum M, Crepaldi G, Gries A, Lefebvre P, Turner P. International trial of long term dexfenfluramine in obesity. Lancet 1989;2:1142-4.
40. Willey KA, Molyneaux LM, Overland JE, Yue DK. The effects of dexfenfluramine on blood glucose control in patients with type 2 diabetes. Diabet Med 1992;9:341-3.
41. Willey KA, Molyneaux LM, Yue DK. Obese patients with type 2 diabetes poorly controlled by insulin and metformin: effects of adjunctive dexfenfluramine therapy on glycaemic control. Diabet Med 1994;11: 701-4.
42. Manning RM, Jung RT, Leese GP, Newton RW. The comparison of four weight reduction strategies aimed at overweight diabetic patients. Diabet Med 1995;12:409-15.
43. The International Primary Pulmonary Hypertension Study (IPPHS). Chest 1994;105(suppl):37s-41s.
44. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, et al. Appetite suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996;335:609-16.
45. Manson JE, Faich GA. Pharmacotherapy for obesity - do the benefits outweigh the risks? N Engl J Med 1996;335:659-60.
46. Cheymol G, Weissenburger J, Poirier JM, Gellee C. The pharmacokinetics of dexfenfluramine in obese and non obese subjects. Br J Clin Pharmacol 1995;39:684-7.
47. Ryan DH, Kaiser P, Bray GA. Sibutramine: a novel new agent for obesity treatment. Obes Res 1995;3(suppl 4):553S-9S.
48. Bray GA, Ryan DH, Gordon D, Heidingsfelder S, Cerise F, Wilson K. A double blind randomized placebo controlled trial of Sibutramine. Obes Res 1996;4:263-70.
49. Weintraub M, Rubio A, Golik A, Byrne L, Scheinbaum ML. Sibutramine in weight control: a dose ranging, efficacy study. Clin Pharmacol Ther 1991;50:330-7.
50. Ryan DH, Bray GA, Wilson JK, Machiavelli RE, Heidingsfelder S, Greenway FL, et al. Treatment for 2 1/2 years with Sibutramine (abstract). Obes Res 1996;4(suppl 1):31s.
51. Astrup A, Toubro S, Christensen NJ, Quaade F. Pharmacology of thermogenic drugs. Am J Clin Nutr 1992;55(suppl):246S-8S.
52. 3-adrenoceptor mRNA in human tissues. Eur J Pharmacol 1995;289:223-8.
53. 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. N Engl J Med 1995;333:352-4.
54. Connacher AA, Jung RT, Mitchell PEG. Weight loss in obese subjects on a restricted diet given BRL 26830A, a new atypical β-adrenoceptor agonist. Br Med J 1988;296:1217-20.
55. Guerciolini R. Mode of action of orlistat. Int J Obes 1997;21(suppl 3):s12-23.
56. Drent ML, van der Veen EA. Lipase inhibition: a novel concept in the treatment of obesity. Int J Obes 1993;17:241-4.
57. Drent ML, Larsson I, William-Olsson T, Quaade FM, Czubayko F, von Bergmann K, et al. Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes 1995;19:221-6.
58. James WPT, Avenell A, Broom J, Whitehead J. A one-year trial to assess the value of orlistat in the management of obesity. Int J Obes 1997; 21(suppl 3):s24-30.
59. Zhi J, Melia AT, Guerciolini R, Chung J, Kinberg J, Hauptman JB, et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994;56:82-5.
60. Zhi J, Melia AT, Funk C, Viger-Chougnet A, Hopfgarter G, Lausecker B, et al. Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers. J Clin Pharmacol 1996;36:1006-11.
61. Weber C, Tam YK, Schmidtke-Schrezenmeier G, Jonkmann JH, van-Brummelen P. Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers. Eur J Clin Pharmacol 1996;51:87-90.
62. Zhi J, Melia AT, Guerciolini R, Koss-Twardy SG, Passe SM, Rakhit A, et al. The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol 1996;36:659-66.
63. Melia AT, Mulligan TE, Zhi J. The effect of orlistat on the pharmacokinetics of phenytoin in healthy volunteers. J Clin Pharmacol 1996;36:654-8.
64. Melia AT, Mulligan TE, Zhi J. Lack of effect of orlistat on the bioavailability of a single dose of nifedipine extended-release tablets (Procardia XL) in healthy volunteers. J Clin Pharmacol 1996;36:352-5.
65. Hartmann D, Guzelhan C, Zuiderwijk PB, Odink J. Lack of interaction between orlistat and oral contraceptives. Eur J Clin Pharmacol 1996;50: 421-4.
66. Melia AT, Zhi J, Koss-Twardy SG, Min BH, Smith BL, Freundlich NL, et al. The influence of reduced dietary fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol 1995;35:840-3.
67. Zhi J, Melia AT, Koss-Twardy SG, Min B, Guerciolini R, Freundlich NL, et al. The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers. J Clin Pharmacol 1995; 35:521-5.
68. Melia AT, Koss-Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol 1996;36:647-53.
69. Zhi J, Melia AT, Koss-Twardy SG, Arora S, Patel IH. The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers. J Clin Pharmacol 1996;36:152-9.
70. Warshaw H, Powers MA, Franz M, Wheeler M. Fat replacers: their use in foods and role in diabetes medical nutrition therapy. Diabetes Care 1996;19:1294-301.
71. Product information. Olean (olestra). Cincinnati, OH: Procter & Gamble, December 1996.
72. Grundy SM, Anastasia JV, Kesaniemi YA, Abrams J. Influence of sucrose polyester on plasma lipoproteins, and cholesterol metabolism in obese patients with and without diabetes mellitus. Am J Clin Nutr 1986; 44:620-9.
73. Glueck CJ, Hastings MM, Allen C, Hogg E, Baehler L, Garside PS, et al. Sucrose polyester and covert caloric dilution. Am J Clin Nutr 1982; 35:1352-9.
74. Glueck CJ, Jandacek R, Hogg E, Allen C, Baehler L, Tewksbury M. Sucrose polyester: substitution for dietary fats in hypocaloric diets in the treatment of familial hypercholesterolemia. Am J Clin Nutr 1983;37: 347-54.
75. Mellies MJ, Vitale C, Jandacek RJ, Lamkin GE, Glueck CJ. The substitution of sucrose polyester for dietary fat in obese, hypercholesterolemic outpatients. Am J Clin Nutr 1985;41:1-12.
76. Cotton JR, Weststrate JA, Blundell JE. Replacement of dietary fat with sucrose polyester: effects on energy intake and appetite control in non-obese males. Am J Clin Nutr 1996;63:891-6.
77. Aggarwal AM, Camilleri M, Phillips SF, Schlagheck TG, Brown ML, Thomforde GM. Olestra, a nondigestible, nonabsorbable fat. Effects on gastrointestinal and colonie transit. Dig Dis Sci 1993;38:1009-14.
78. Blackburn H. Olestra and the FDA. N Engl J Med 1996;334:984-6.
79. Jones DY, Miller KW, Koonsvitsky BP, Eben ML, Lin PYT, Jones MB, et al. Serum 25-hydroxyvitamin D concentrations of free-living subjects consuming olestra. Am J Clin Nutr 1991;53:1281-7.
80. Jones DY, Koonsvitsky BP, Ebert ML, Jones MB, Lin PYT, Will BH, et al. Vitamin K status of free-living subjects consuming olestra. Am J Clin Nutr 1991;53:943-6.
81. Weststrate JA, van het Hof KH. Sucrose polyester and plasma carotenoid concentrations in healthy subjects. Am J Clin Nutr 1995;62:591-7.
82. Roberts RJ, Leff RD. Influence of absorbable and nonabsorbable lipids and lipidlike substances on drug bioavailability. Clin Pharmacol Ther 1989;45:299-304.
83. Miller KW, Williams DS, Carter SB, Jones MB, Mishell DR The effect of olestra on systemic levels of oral contraceptives. Clin Pharmacol Ther 1990;48:34-40.
84. Benmoussa K, Sabouraud A, Scherrmann JM, Brossard D, Bourre JM. Effects of fat substitutes, sucrose polyester and tricarballylate triester, on digitoxin absorption in the rat. J Pharm Pharmacol 1993;45:692-6.
85. Benmoussa K, Sabouraud A, Scherrmann JM, Bourre JM. Cyclosporin absorption is impaired by the fat substitutes, sucrose polyester and tricarballylate triester, in the rat. Pharm Res 1994;11:1458-61.
86. Benmoussa K, Scherrmann JM, Bourre JM. Inhibition of colchicine absorption by the fat substitutes, sucrose polyester and tricarballylate triester, in the rat. Life Sci 1995;56:117-24.
87. Bray GA. Peptides and food intake. Nutrient intake is modulated by peripheral peptide administration. Obes Res 1995;3(suppl 4):569s-72s.
88. Zarjevski N, Cusin I, Vettor R, Rohner-Jeanrenaud F, Jeanrenaud B. Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity. Endocrinology 1993;133:1753-8.
89. Bray GA. Leptin and leptinomania. Lancet 1996;348:140.
90. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995;269:543-6.
91. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292-5.
92. Caro JF, Kolaczynski JW, Nyce MR, Ohannesian JP, Opentanova I, Goldman WH, et al. Decreased cerebrospinal-fluid/serum leptin ratio in obesity; a possible mechanism for leptin resistance. Lancet 1996;348: 159-61.
93. F-D-C Rep 1997;May 19:4.